TG101348 (SAR302503) (Synonyms: Fedratinib, SAR302503) |
Katalog-Nr.GC14324
One-Click Copy Product Info
|
TG101348 (SAR302503) is a selective small-molecule inhibitor of JAK2 with an IC50 value of 3nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 936091-26-8
Sample solution is provided at 25 µL, 10mM.
TG101348 (SAR302503) is a selective small-molecule inhibitor of JAK2 with an IC50 value of 3nM[1]. TG101348 is primarily approved for myelofibrosis (MF) and is also under active investigation for myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes and chronic neutrophilic leukemia (CNL)[2].
In vitro, TG101348 (300 and 600nM) preincubation on human erythro-megakaryocytic UT7/Epo cells for 30min prior to stimulation with 10U/ml erythropoietin (EPO) strongly suppressed JAK2-mediated STAT5 phosphorylation and AKT activation, and markedly reduced GATA-1 S310 phosphorylation[3]. TG101348 (250nM, 500nM and 2μM) application on pancreatic ductal adenocarcinoma (PDAC) cell lines in combination with the MEK inhibitor trametinib and KRAS inhibitors for 48h led to significant antitumor effects by suppressing ERK and STAT3 phosphorylation and significantly diminishing AKT phosphorylation[4].
In vivo, TG101348 (60mg/kg) in 200μL volume administrated into mouse models of hemophagocytic lymphohistiocytosis (HLH) via oral gavage twice daily from days 4 to 8 or days 4 through 29 after LCMV infection. TG101348 treatment showed no survival benefit, but improved anemia and thrombocytopenia by inhibiting IFN-γ signaling and modulating G-CSF effects[5]. TG101348 was given to high-fat high-cholesterol Western diet (WD)–fed Apoe−/− mice orally via gavage at 120mg/kg/day for the first week and then by 240mg/kg/day for the remaining 9 weeks. TG101348 significantly reduced neutrophilia and monocytosis, reduced atherosclerotic lesion area by about 74% in the aorta, and suppressed STAT5 and ERK1/2 phosphorylation in bone marrow cells[6]. TG101348 (5mg/kg body weight) was injected (i.p.) into ischemia-reperfusion (I/R)-AKI mice model 24h once in advance before surgery. TG101348 ameliorated renal tubular cell injury and protected renal function by inhibiting ferroptosis through TRIM21 expression downregulation[7].
References:
[1] Wernig G, Kharas M G, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.Cancer Cell. 2008 Apr;13(4):311-20.
[2] Coltoff A, Mascarenhas J. Fedratinib in 2025 and beyond: indications and future applications.Blood Adv. 2025 Apr 22;9(8):1907-1915.
[3] Geron I, Abrahamsson A E, Barroga C F, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.Cancer Cell. 2008 Apr;13(4):321-30.
[4] Miyazaki S, Kitazawa M, Nakamura S, et al. Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2.Mol Oncol. 2025 Feb;19(2):377-390.
[5] Keenan C, Albeituni S, Oak N, et al. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.Blood. 2024 Jun 6;143(23):2386-2400.
[6] Tang Y, Liu W L, Wang W, et al. Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice. Cardiovasc Drugs Ther. 2020 Apr;34(2):145-152.
[7] Sun X L, Huang N, Li P, et al. TRIM21 ubiquitylates GPX4 and promotes ferroptosis to aggravate ischemia/reperfusion-induced acute kidney injury. Life Sci. 2023 May 15:321:121608.
| Cell experiment [1]: | |
Cell lines | Human erythro-megakaryocytic UT7/Epo cells |
Preparation Method | The human erythro-megakaryocytic UT7/Epo cells were starved in 0.1% FBS in IMDM for 24hr prior to stimulation. Cells were preincubated with various inhibitors TG101348 (300 and 600nM) 1hr prior to stimulation with 10U/ml EPO for 30min.. |
Reaction Conditions | 300 and 600nM; 30min |
Applications | TG101348 strongly suppressed JAK2-mediated STAT5 phosphorylation and AKT activation, and markedly reduced GATA-1 S310 phosphorylation. |
| Animal experiment [1: | |
Animal models | Immunocompromised RAG2-/- γc -/- mice |
Preparation Method | Transplanted RAG2-/- γc -/- mice were also treated with a selective JAK2 inhibitor TG101348 (120mg/kg) or vehicle (DMSO) by oral gavage twice daily for 12 days. |
Dosage form | 120mg/kg; oral gavage; twice daily for 12 days |
Applications | TG101348 significantly reduced erythroid engraftment driven by JAK2V617F+ human progenitors. |
References: | |
| Cas No. | 936091-26-8 | SDF | |
| Überlieferungen | Fedratinib, SAR302503 | ||
| Chemical Name | N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide | ||
| Canonical SMILES | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4 | ||
| Formula | C27H36N6O3S | M.Wt | 524.68 |
| Löslichkeit | ≥ 26.2 mg/mL in DMSO, ≥ 6.69 mg/mL in EtOH with ultrasonic and warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9059 mL | 9.5296 mL | 19.0592 mL |
| 5 mM | 381.2 μL | 1.9059 mL | 3.8118 mL |
| 10 mM | 190.6 μL | 953 μL | 1.9059 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)